Shares of diagnostics company Guardant Health (NASDAQ:GH)
fell 8.8% in the morning session after the company announced the pricing of an upsized convertible senior notes offering and a public stock offering, raising concerns about dilution for existing shareholders. The company priced $350 million of convertible senior notes, an increase from the previously announced $300 million offering. Concurrently, Guardant Health priced a public offering of more than 3.3 million shares of its common stock at $90.00 per share. Such financial moves, while raising capital for the company, often lead to a drop in stock price. This is because the issuance of new shares and securities that can be converted into shares can dilute the ownership stake of current investors, making each existing share represent a smaller piece of the company.
Guardant Health’s third quarter was marked by robust revenue growth and a positive market reaction, with outperformance across its main business lines. Management attributed these results to accelerating oncology test volumes, continued adoption of the Guardant360 platform, and the early commercial success of Shield in cancer screening. Co-CEO Helmy Eltoukhy highlighted the company’s ability to deliver “broad-based growth across our business,” citing stronger biopharma partnerships and effective cost controls, particularly in the Reveal and Shield product lines. The company’s progress in expanding its clinical utility and reducing per-test costs contributed meaningfully to margin improvements this quarter.
Exciting developments are taking place for the stocks in this article.
They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Diagnostics company Guardant Health (NASDAQ:GH) announced better-than-expected revenue in Q3 CY2025, with sales up 38.5% year on year to $265.2 million. The company’s full-year revenue guidance of $967.5 million at the midpoint came in 4.9% above analysts’ estimates. Its non-GAAP loss of $0.39 per share was 20.3% above analysts’ consensus estimates.
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Diagnostics company Guardant Health (NASDAQ:GH) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 38.5% year on year to $265.2 million. The company’s full-year revenue guidance of $967.5 million at the midpoint came in 4.9% above analysts’ estimates. Its non-GAAP loss of $0.39 per share was 20.3% above analysts’ consensus estimates.
